These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 28577031)
1. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1. Trevisson E; Cassina M; Opocher E; Vicenzi V; Lucchetta M; Parrozzani R; Miglionico G; Mardari R; Viscardi E; Midena E; Clementi M J Neurooncol; 2017 Sep; 134(2):279-287. PubMed ID: 28577031 [TBL] [Abstract][Full Text] [Related]
2. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature. Friedrich RE; Nuding MA Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519 [TBL] [Abstract][Full Text] [Related]
3. The Utility of Early Brain MRI for Patients with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Long-Term Follow-Up in a Tertiary Referral Hospital. Rony C; Aharoni S; Halevy A Neuropediatrics; 2022 Oct; 53(5):370-375. PubMed ID: 35381604 [TBL] [Abstract][Full Text] [Related]
4. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Blanchard G; Lafforgue MP; Lion-François L; Kemlin I; Rodriguez D; Castelnau P; Carneiro M; Meyer P; Rivier F; Barbarot S; Chaix Y; Eur J Paediatr Neurol; 2016 Mar; 20(2):275-281. PubMed ID: 26774135 [TBL] [Abstract][Full Text] [Related]
6. Growth hormone excess in children with neurofibromatosis type-1 and optic glioma. Cambiaso P; Galassi S; Palmiero M; Mastronuzzi A; Del Bufalo F; Capolino R; Cacchione A; Buonuomo PS; Gonfiantini MV; Bartuli A; Cappa M; Macchiaiolo M Am J Med Genet A; 2017 Sep; 173(9):2353-2358. PubMed ID: 28631895 [TBL] [Abstract][Full Text] [Related]
7. Optic pathway glioma in children: 10 years of experience in a single institution. Doganis D; Pourtsidis A; Tsakiris K; Baka M; Kouri A; Bouhoutsou D; Varvoutsi M; Servitzoglou M; Dana H; Kosmidis H Pediatr Hematol Oncol; 2016 Mar; 33(2):102-8. PubMed ID: 27007263 [TBL] [Abstract][Full Text] [Related]
8. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859 [TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Thiagalingam S; Flaherty M; Billson F; North K Ophthalmology; 2004 Mar; 111(3):568-77. PubMed ID: 15019338 [TBL] [Abstract][Full Text] [Related]
10. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Dalla Via P; Opocher E; Pinello ML; Calderone M; Viscardi E; Clementi M; Battistella PA; Laverda AM; Da Dalt L; Perilongo G Neuro Oncol; 2007 Oct; 9(4):430-7. PubMed ID: 17704361 [TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children]. Florent C; Beylerian M; Mairot K; Dambricourt L; André N; David T; Girard N; Audic F; Denis D J Fr Ophtalmol; 2022 Feb; 45(2):173-184. PubMed ID: 34972579 [TBL] [Abstract][Full Text] [Related]
12. Optic Gliomas in Neurofibromatosis Type 1. Parkhurst E; Abboy S J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):334-338. PubMed ID: 27537249 [TBL] [Abstract][Full Text] [Related]
13. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study. Henning AM; Handrup MM; Kjeldsen SM; Larsen DA; Ejerskov C Orphanet J Rare Dis; 2021 Nov; 16(1):489. PubMed ID: 34809690 [TBL] [Abstract][Full Text] [Related]
14. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma. Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625 [TBL] [Abstract][Full Text] [Related]
17. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients. Pinheiro SL; Maciel J; Cavaco D; Figueiredo AA; Damásio IL; Donato S; Passos J; Simões-Pereira J Hormones (Athens); 2023 Mar; 22(1):79-85. PubMed ID: 36269545 [TBL] [Abstract][Full Text] [Related]
18. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort. Falzon K; Drimtzias E; Picton S; Simmons I Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527 [TBL] [Abstract][Full Text] [Related]
19. Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas. Byrne S; Connor S; Lascelles K; Siddiqui A; Hargrave D; Ferner RE J Neurooncol; 2017 Jul; 133(3):609-614. PubMed ID: 28593402 [TBL] [Abstract][Full Text] [Related]
20. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. King A; Listernick R; Charrow J; Piersall L; Gutmann DH Am J Med Genet A; 2003 Oct; 122A(2):95-9. PubMed ID: 12955759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]